Medical network - on March 14, the current a-share during the annual reports published peak, several pharmaceutical companies have also released the annual report, by collating, found that the most profitable should not hengrui, but...
▍ our pharmaceutical enterprises profit growth than income growth
At present, China's A shares proprietary Chinese medicine, biological, pharmaceutical and chemical pharmaceutical (API) nearly 180 publicly traded companies, as of March 12, 16 companies released annual report.
Summary of these enterprise's performance, the total business income grew 10.02% year-on-year in 2015, while net profit rose nearly twice as much as business income, up to 18.44%. The growth speed and the pharmaceutical industry in 2016 is expected to total sales revenue and profit growth are consistent.
Although the statistical caliber has certain differences, but still has a certain value. The specific contrast as follows:
Note: 16 a-share listed companies for the company, hengrui pharmaceutical, wide economic essence pharmaceutical co., Shanghai KaiBao, pharmaceutical, changchun high-tech, China resources, China resources double crane, bo teng lump-sum corporation, China pharmaceutical, WoHua medicine, east China pharmaceutical, Harbin pharmaceutical co, daughter pharmaceutical, hokuriku pharmaceutical and jianmin group; Pharmaceutical industry include chemical API manufacture, chemical medicine preparations, Chinese medicine yinpian processing, proprietary Chinese medicine manufacturing and biological medicine manufacture, hygiene materials and medical supplies and medical equipment seven architectural industry.
▍ turned out to be the company's most profitable enterprises
As of March 12, A shares have been released 2016 annual report of 16 companies, proprietary Chinese medicine enterprises have eight, has seven chemical pharmaceutical, biopharmaceutical companies one.
Business income of more than ten billion yuan business with east China pharmaceutical and hengrui pharmaceutical, Harbin pharmaceutical shares three; 50 ~ 10 billion yuan of enterprise with China resources, the company and China resources lump-sum double crane three; 10 ~ 5 billion yuan KaiBao, changchun high-tech enterprises with Shanghai, teng co, China pharmaceutical industry, pharmaceutical industry and daughter jianmin group six, the remaining three and the rest was below 1 billion dollars.
From net income, net profit more than $1 billion in a company, hengrui pharmaceutical, China resources and lump-sum east China pharmaceutical four; Broad economic essence pharmaceutical co., Shanghai KaiBao, pharmaceutical, changchun high-tech, China resources double crane, teng co, China pharmaceutical, Harbin pharmaceutical shares and daughter pharmaceutical nine companies are between 1 and 1 billion yuan; WoHua medicine, hokuriku pharmaceutical and jianmin group net profit in one hundred million yuan of the following three companies.
Assets net profit margin is mainly used to measure the ability to make profits, companies use assets reflects the total assets of the enterprise efficiency, says the number of enterprise assets can obtain net profit per unit, the higher the ratio, the stronger the enterprise all assets profitability.
From this perspective, has 16 of the pharmaceutical enterprises of the annals of the communique net interest rate, the most profitable enterprises not "developing" hengrui pharmaceutical pharmaceutical enterprises in our country, but the proprietary Chinese medicine industry in our country luxuries on behalf of the company, 30% of the net interest rates close to 30%, followed by 23.34% of hengrui pharmaceutical.
Other net interest rate more than 15% of the enterprises and widely and essence of pharmaceutical and pharmaceutical industry, Shanghai KaiBao changchun high-tech four. Has now been released annual report of the basic financial indicators such as drug firms operating income and net profit in the following table:
(note: the data from the annual reports of listed companies, for reference)
▍ representative enterprises
The company: the company is located in the birthplace of donkey-hide gelatin, has widely cognitive mental resources advantage, as the industry's first brand, market advantage is obvious. The company for the national intangible cultural heritage representative inheritance person enterprise, the only have irreplaceable brand resources advantage. Continuity in one thousand national secret traditional process, as well as the automatic and intelligent modern production technology; Involved in making a number of industry standards, have a large number of donkey-hide gelatin traditional prescription, secret recipe, leading the industry standards, product research and development, and leading technology advantages.
From the upstream raw material base construction, control the donkey skin acquisition terminal, to the downstream OTC terminal, business super, hospitals, self-built chain such as marketing, terminal control, formed a complete industrial chain of control pattern. In shandong, Inner Mongolia, liaoning and other places set up raw material bases, in foreign countries to establish a procurement network, to achieve control of self-restraint, paying equal attention to domestic and international, to ensure sustainable development of the company. And top chain form stable strategic cooperation, direct and key chain terminal sales increased steadily year by year, the network advantage is obvious.
But, the enterprise sales and profit growth in recent years thanks to raise prices for many times, have gelatin into the luxuries of traditional Chinese medicine industry in our country. Exactly how far can? We have to wait and see.
Hengrui pharmaceutical: hengrui pharmaceutical is benchmarking and representatives of innovation in our country, research and development is a must see window:
One is the innovation of harvest. Innovation gradually played a stimulating effect on the company's performance growth, harvest for its innovative medicine path, iresearch and cloth is the main driver.
Secondly, the preparation export revenues. Represented by cyclophosphamide companies export products, standardize the market sales abroad has grown steadily, to promote the company's operating revenue and profit growth. In 2016, the company continued to strengthen the implementation of the strategy of internationalization, actively expand overseas markets. Generic international aspect, the inhaled sevoflurane well sold in the United States, for injection cyclophosphamide, etc. Series of products has been a steady rise in sales; Europe, America, Japan standardize market each project registration filing work as planned; Other emerging markets such as Russia, South America, Middle East, gradually strengthen the registration.
Three is the company's product structure optimization. With the company product structure adjustment, the anti-tumor medicine for years a the dominance is being gradually changed. Hengrui pharmaceutical infusion with anesthesia, contrast, and characteristic of the anti-tumor medicine products of the company in their respective treatment field gradually expand the market, as well as the enterprise strong research and development strength, little surprise in the next few years continue to steady growth.
Huarun san-jiu: CRC is the ego and lump-sum and representatives of Chinese traditional medicine prescription drug companies committed to become the "leading" self diagnosis and treatment and "Chinese medicine value creators". Self and mainly include the OTC and large health related business, the core categories including cold, stomach, skin, pediatrics, etc. Company has been in China for four consecutive years non-prescription drugs production enterprises ranked the first, 999 brands in China many times Chinese medicine list of word of mouth.
Company enjoy high reputation in Chinese traditional medicine prescription drug industry, the product coverage of heart head blood-vessel, antitumor, digestive system, orthopedic, pediatrics and other therapeutic areas, with the cords attached injection, injection, cars ace blood through soft capsule, isn HuaChan tablet and injection, mold Zhi yellow oral liquid, and other traditional Chinese medicine prescription drug varieties, across the country have many GAP planting base of Chinese medicinal materials. Company as one of traditional Chinese medicine formula particles pilot production enterprises, the production of more than 600 kinds of varieties of single formula particles. With the implementation of China's traditional Chinese medicine (TCM) support policy dividend, the whole industry chain development, traditional Chinese medicine (TCM) industry enterprises in the next few years is expected to sustain growth. |
